Autoimmunity and environment: Am i at risk?

Clinical Reviews in Allergy and Immunology

Volumn 42, Issue 2, 2012, Pages 199-212

  Smyk, Daniel ^a   Rigopoulou, Eirini I ^b   Baum, Harold ^a   Burroughs, Andrew K ^c   Vergani, Diego ^a   Bogdanos, Dimitrios P ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

AMA; Estrogen; Genetics; PBC; Risk factors; Urinary tract infections; Xenobiotics

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; HLA DR8 ANTIGEN; HLA DRB1 ANTIGEN; IMMUNOGLOBULIN M; PROTEIN SHC; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CHROMOSOME 17Q; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; ESCHERICHIA COLI; ESTROGEN DEFICIENCY; ETHNICITY; FAMILY HISTORY; GASTROESOPHAGEAL REFLUX; GENETIC SUSCEPTIBILITY; HEPATITIS A; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; NONHUMAN; PATHOGENESIS; PRIMARY BILIARY CIRRHOSIS; PROTEIN EXPRESSION; PRURITUS; PSORIASIS; RAYNAUD PHENOMENON; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; SJOEGREN SYNDROME; SMOKING; TONSILLECTOMY; URINARY TRACT INFECTION;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; ENVIRONMENTAL EXPOSURE; ESTROGENS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER CIRRHOSIS, BILIARY; RISK; URINARY TRACT INFECTIONS; XENOBIOTICS;

EID: 84862293160     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-011-8259-x     Document Type: Review

References (190)

1. Mackay IR (2005) The etiopathogenesis ofautoimmunity. Semin Liver Dis 25(3):239-250
2. Hewagama A, Richardson B (2009) The genetics and epigenetics of autoimmune diseases. J Autoimmun 33(1):3-11
3. Wandstrat A, Wakeland E (2001) The genetics of complex autoimmune diseases: non-MHC susceptibility genes. Nat Immunol 2(9):802-809
4. Ahmed SA, Hissong BD, Verthelyi D, Donner K, Becker K, Karpuzoglu-Sahin E (1999) Gender and risk of autoimmune diseases: possible role ofestrogenic compounds. Environ Health Perspect 107(Suppl 5):681-686 (Pubitemid 29527770)
5. Coppieters KT, von Herrath MG (2011) Viruses and Cytotoxic T Lymphocytes in Type 1 Diabetes. Clin Rev Allergy Immunol (in press)
6. Christen U, Hintermann E, Holdener M, von Herrath MG (2010) Viral triggers for autoimmunity: is the 'glass of molecular mimicry' half full or half empty? J Autoimmun 34(1):38-44
7. Maverakis E, Miyamura Y, Bowen MP, Correa G, Ono Y, Goodarzi H(2010) Light, includingultraviolet. JAutoimmun34(3):J247-257
8. Molina V, Shoenfeld Y (2005) Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity 38(3):235-245 (Pubitemid 40959897)
9. Bach JF (2005) Infections and autoimmune diseases. J Auto-immun 25(Suppl):74-80
10. Leslie RD, Hawa M (1994) Twin studies in auto-immune disease. Acta Genet Med Gemellol Roma 43(1-2):71-81 (Pubitemid 24305877)
11. Selmi C, Mayo MJ, Bach N, Ishibashi H, Invernizzi P, Gish RG, Gordon SC, Wright HI, Zweiban B, Podda M, Gershwin ME (2004) Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology 127(2):485-492 (Pubitemid 39091897)
12. Cooper GS, Wither J, Bernatsky S, Claudio JO, Clarke A, Rioux JD, Fortin PR (2010) Occupational and environmental exposures and risk of systemic lupus erythematosus: silica, sunlight, solvents. Rheumatology (Oxford) 49(11):2172-2180
13. Jarvinen P, Aho K (1994) Twin studies in rheumatic diseases. Semin Arthritis Rheum 24(1):19-28
14. Youinou P, Pers JO, Gershwin ME, Shoenfeld Y (2010) Geo-epidemiology and autoimmunity J Autoimmun 34(3):J163-J167
15. Lleo A, Selmi C, Invernizzi P, Podda M, Gershwin ME (2008) The consequences of apoptosis in autoimmunity J Autoimmun 31 (3):257-262
16. Chang C, Gershwin ME (2010) Drugs and autoimmunity-a contemporary review and mechanistic approach. J Autoimmun 34 (3):J266-275
17. Costenbader KH, Karlson EW (2006) Cigarette smoking and autoimmune disease: what can we learn from epidemiology? Lupus 15(11):737-745
18. Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, Lindor KD, Kaplan MM, Vierling JM (2005) Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 42(5):1194-1202 (Pubitemid 43112687)
19. Arnson Y, Shoenfeld Y, Amital H (2010) Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Auto-immun 34(3):J258-265
20. Sugiyama D, Nishimura K, Tamaki K, Tsuji G, Nakazawa T, Morinobu A, Kumagai S (2010) Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 69(1):70-81
21. Lleo A, Battezzati PM, Selmi C, Gershwin ME, Podda M (2008) Is autoimmunity a matter of sex? Autoimmun Rev 7(8):626-630
22. Levy Y Rotman-Pikielny P, Ehrenfeld M, Shoenfeld Y (2009) Silicone breast implantation-induced scleroderma: description of four patients and a critical review of the literature. Lupus 18 (13):1226-1232
23. Bogdanos DP, Rigopoulou EI (2006) Self-mimicking autoim-mune domains of hepatitis C virus core antigen. Vaccine 24(37-39):6173-6174 (Pubitemid 44262414)
24. Bogdanos DP, Rigopoulou EI (2007) Viral/self-mimicry and immunological cross-reactivity as a trigger of hepatic C virus associated autoimmune diabetes. Diab Res Clin Pract 77(1):155-156 (Pubitemid 46613915)
25. Bogdanos DP, Smith H, Ma Y, Baum H, Mieli-Vergani G, Vergani D (2005) A study of molecular mimicry and immuno-logical cross-reactivity between hepatitis B surface antigen and myelin mimics. Clin Dev Immunol 12(3):217-224 (Pubitemid 43205646)
26. Nancy AL, Shoenfeld Y (2008) Chronic fatigue syndrome with autoantibodies-the result of an augmented adjuvant effect of hepatitis-B vaccine and silicone implant. Autoimmun Rev 8 (1):52-55
27. Cooper GS, Parks CG (2004) Occupational and environmental exposures as risk factors for systemic lupus erythematosus. Curr Rheumatol Rep 6(5):367-374
28. Parks CG, Conrad K, Cooper GS (1999) Occupational exposure to crystalline silica and autoimmune disease. Environ Health Perspect 107(Suppl 5):793-802 (Pubitemid 29527785)
29. Pfau JC, Brown JM, Holian A (2004) Silica-exposed mice generate autoantibodies to apoptotic cells. Toxicology 195(2-3):167-176 (Pubitemid 38125117)
30. Brown JM, Archer AJ, Pfau JC, Holian A (2003) Silica accelerated systemic autoimmune disease in lupus-prone New Zealand mixed mice. Clin Exp Immunol 131(3):415-421 (Pubitemid 36324131)
31. Parks CG, Cooper GS (2006) Occupational exposures and risk of systemic lupus erythematosus: a review of the evidence and exposure assessment methods in population- and clinic-based studies. Lupus 15(11):728-736
32. Bogdanos DP, Lenzi M, Okamoto M, Rigopoulou EI, Muratori P, Ma Y Muratori L, Tsantoulas D, Mieli-Vergani G, Bianchi FB, Vergani D (2004) Multiple viral/self immunological cross-reactivity in liver kidney microsomal antibody positive hepatitis C virus infected patients is associated with the possession of HLA B51. Int J Immunopathol Pharmacol 17(1):83-92 (Pubitemid 39572192)
33. Bogdanos DP, McFarlane IG (2003) Cytochrome P450 2A6 meets P450 2D6: an enigma of viral infections and autoimmu-nity. J Hepatol 39(5):860-863 (Pubitemid 37372199)
34. Arnson Y, Amital H, Shoenfeld Y (2007) Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis 66(9): 1137-1142 (Pubitemid 47309727)
35. Kriegel MA, Manson JE, Costenbader KH (2011) Does Vitamin D Affect Risk of Developing Autoimmune Disease?: A Systematic Review. Semin Arthritis Rheum (in press)
36. Lerner A, Shapira Y, Agmon-Levin N, Pacht A, Ben-Ami Shor D, Lopez HM, Sanchez-Castanon M, Shoenfeld Y (2011) The Clinical Significance of 25OH-Vitamin D Status in Celiac Disease. Clin Rev Allergy Immunol (in press)
37. Pelajo CF, Lopez-Benitez JM, Miller LC (2010) Vitamin D and autoimmune rheumatologic disorders. Autoimmun Rev 9 (7):507-510
38. Broder AR, Tobin JN, Putterman C (2010) Disease-specific definitions of vitamin D deficiency need to be established in autoimmune and non-autoimmune chronic diseases: a retrospective comparison ofthree chronic diseases. Arthritis Res Ther 12(5):R191
39. van Halteren AG, Tysma OM, van Etten E, Mathieu C, Roep BO (2004) 1alpha, 25-dihydroxyvitamin D3 or analogue treated dendritic cells modulate human autoreactive T cells via the selective induction ofapoptosis. J Autoimmun 23(3):233-239 (Pubitemid 40288105)
40. Gauzzi MC, Purificato C, Donato K, Jin Y, Wang L, Daniel KC, Maghazachi AA, Belardelli F, Adorini L, Gessani S (2005) Suppressive effect of 1alpha, 25-dihydroxyvitamin D3 on type I IFN-mediated monocyte differentiation into dendritic cells: impairment of functional activities and chemotaxis. J Immunol 174(1):270-276 (Pubitemid 40007413)
41. Kaplan MM, Gershwin ME (2005) Primary biliary cirrhosis. N Engl J Med 353(12):1261-1273 (Pubitemid 41345948)
42. Hohenester S, Oude-Elferink RP, Beuers U (2009) Primary biliary cirrhosis. Semin Immunopathol 31(3):283-307
43. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ (2009) Primary biliary cirrhosis. Hepatology 50 (1):291-308
44. Mitchison HC, Bassendine MF, Hendrick A, Bennett MK, Bird G, Watson AJ, James OF (1986) Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis? Hepatology 6(6):1279-1284 (Pubitemid 17210555)
45. Neuberger J (1997) Primary biliary cirrhosis. Lancet 350 (9081):875-879 (Pubitemid 27404357)
46. Prince MI, Chetwynd A, Craig WL, Metcalf JV, James OF (2004) Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut 53(6):865-870 (Pubitemid 38662138)
47. Bogdanos DP, Komorowski L (2011) Disease-specific autoantibodies in primary biliary cirrhosis. Clin Chim Acta 412(7-8):502-512
48. Bogdanos DP, Invernizzi P, Mackay IR, Vergani D (2008) Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol 14(21):3374-3387
49. Bogdanos DP, Baum H, Vergani D (2003) Antimitochondrial and other autoantibodies. Clin Liver Dis 7(4):759-777 (Pubitemid 37229503)
50. Kumagi T, Heathcote EJ (2008) Primary biliary cirrhosis. Orphanet J Rare Dis 3:1
51. James OF, Bhopal R, Howel D, Gray J, Burt AD, Metcalf JV (1999) Primary biliary cirrhosis once rare, now common in the United Kingdom? Hepatology 30(2):390-394 (Pubitemid 29357502)
52. Kim WR, Lindor KD, Locke GR 3rd, Therneau TM, Homburger HA, Batts KP, Yawn BP, Petz JL, Melton LJ 3rd, Dickson ER (2000) Epidemiology and natural history of primary biliary cirrhosis in aUS community. Gastroenterology 119(6):1631-1636 (Pubitemid 32198688)
53. Dahnrich C, Pares A, Caballeria L, Rosemann A, Schlumberger W, Probst C, Mytilinaiou M, Bogdanos D, Vergani D, Stocker W, Komorowski L (2009) New ELISA for detecting primary biliary cirrhosis-specific antimitochondrial antibodies. Clin Chem 55(5):978-985
54. Liu H, Norman GL, Shums Z, Worman HJ, Krawitt EL, Bizzaro N, Vergani D, Bogdanos DP, Dalekos GN, Milkiewicz P, Czaja AJ, Heathcote EJ, Hirschfield GM, Tan EM, Miyachi K, Bignotto M, Battezzati PM, Lleo A, Leung PS, Podda M, Gershwin ME (2010) Invernizzi P PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. J Auto-immun 35(4):436-442
55. Rigopoulou EI, Davies ET, Bogdanos DP, Liaskos C, Mytilinaiou M, Koukoulis GK, Dalekos GN, Vergani D (2007) Antimitochon-drial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis. Liver Int 27(9):1226-1231 (Pubitemid 47543151)
56. Rigopoulou EI, Bogdanos DP, Liaskos C, Koutsoumpas A, Baum H, Vergani D, Dalekos GN (2007) Anti-mitochondrial antibody immunofluorescent titres correlate with the number and intensity of immunoblot-detected mitochondrial bands in patients with primary biliary cirrhosis. Clin Chim Acta 380(1-2):118-121 (Pubitemid 46509627)
57. Gabeta S, Norman GL, Liaskos C, Papamichalis PA, Zografos T, Garagounis A, Rigopoulou EI, Dalekos GN (2007) Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis. J Clin Immunol 27(4):378-387 (Pubitemid 46906660)
58. Van Norstrand MD, Malinchoc M, Lindor KD, Therneau TM, Gershwin ME, Leung PS, Dickson ER, Homburger HA (1997) Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: relationship of levels of autoantibodies to disease progression. Hepatology 25(1):6-11 (Pubitemid 27014977)
59. Wesierska-Gadek J, Penner E, Battezzati PM, Selmi C, Zuin M, Hitchman E, Worman HJ, Gershwin ME, Podda M, Invernizzi P (2006) Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 43(5):1135-1144 (Pubitemid 43724638)
60. Bogdanos DP, Liaskos C, Pares A, Norman G, Rigopoulou EI, Caballeria L, Dalekos GN, Rodes J, Vergani D (2007) Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis. Hepatology 45(6):1583-1584
61. Bogdanos DP, Liaskos C, Rigopoulou EI, Dalekos GN (2006) Anti-mitochondrial antibodies in patients with systemic lupus erythema-tosus: revealingtheunforeseen. ClinChimActa373(1-2):183-185
62. Bogdanos DP, Pares A, Rodes J, Vergani D (2004) Primary biliary cirrhosis specific antinuclear antibodies in patients from Spain. Am J Gastroenterol 99(4):763-765 (Pubitemid 38607983)
63. Bogdanos DP, Vergani D, Muratori P, Muratori L, Bianchi FB (2004) Specificity of anti-sp100 antibody for primary biliary cirrhosis. Scand J Gastroenterol 39(4):405-407
64. Courvalin JC, Worman HJ (1997) Nuclear envelope protein autoanti-bodies in primary biliary cirrhosis. Semin Liver Dis 17(1):79-90 (Pubitemid 27157374)
65. Invernizzi P, Crosignani A, Battezzati PM, Covini G, De Valle G, Larghi A, Zuin M, Podda M (1997) Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hep-atology 25(5):1090-1095 (Pubitemid 27199932)
66. Invernizzi P, Podda M, Battezzati PM, Crosignani A, Zuin M, Hitchman E, Maggioni M, Meroni PL, Penner E, Wesierska-Gadek J (2001) Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J Hepatol 34(3):366-372 (Pubitemid 32240814)
67. Miyachi K, Hankins RW, Matsushima H, Kikuchi F, Inomata T, Horigome T, Shibata M, Onozuka Y, Ueno Y, Hashimoto E, Hayashi N, Shibuya A, Amaki S, Miyakawa H (2003) Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis: a multicenter study. J Autoimmun 20(3):247-254 (Pubitemid 36561490)
68. Muratori P, Muratori L, Ferrari R, Cassani F, Bianchi G, Lenzi M, Rodrigo L, Linares A, Fuentes D, Bianchi FB (2003) Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 98(2):431-437 (Pubitemid 36232395)
69. Rigopoulou EI, Davies ET, Pares A, Zachou K, Liaskos C, Bogdanos DP, Rodes J, Dalekos GN, Vergani D (2005) Prevalence and clinical significance of isotype specific antinu-clear antibodies in primary biliary cirrhosis. Gut 54(4):528-532 (Pubitemid 40395506)
70. Mackay IR, Whittingham S, Fida S, Myers M, Ikuno N, Gershwin ME, Rowley MJ (2000) The peculiar autoimmunity ofprimary biliary cirrhosis. Immunol Rev 174:226-237 (Pubitemid 30201391)
71. Gershwin ME, Mackay IR (2008) The causes ofprimary biliary cirrhosis: Convenient and inconvenient truths. Hepatology 47 (2):737-745 (Pubitemid 351280742)
72. Vergani D, Bogdanos DP, Baum H (2004) Unusual suspects in primary biliary cirrhosis. Hepatology 39(1):38-41 (Pubitemid 38461464)
73. Hirschfield GM, Heathcote EJ, Gershwin ME (2010) Pathogen-esis of cholestatic liver disease and therapeutic approaches. Gastroenterology 139(5):1481-1496
74. Jones DE (2007) Pathogenesis of primary biliary cirrhosis. Gut 56(11):1615-1624
75. Gershwin ME, Mackay IR (1991) Primary biliary cirrhosis: paradigm or paradox for autoimmunity. Gastroenterology 100 (3):822-833
76. Donaldson PT, Baragiotta A, Heneghan MA, Floreani A, Venturi C, Underhill JA, Jones DE, James OF, Bassendine MF (2006) HLA class II alleles, genotypes, haplotypes, and amino acids in primary biliary cirrhosis: a large-scale study. Hepatology 44(3):667-674 (Pubitemid 44433723)
77. Hirschfield GM, Liu X, Xu C, Lu Y, Xie G, Lu Y, Gu X, Walker EJ, Jing K, Juran BD, Mason AL, Myers RP, Peltekian KM, Ghent CN, Coltescu C, Atkinson EJ, Heathcote EJ, Lazaridis KN, Amos CI, Siminovitch KA (2009) Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 360(24):2544-2555
78. LiuX, Invernizzi P, Lu Y, Kosoy R, Lu Y, Bianchi I, Podda M, Xu C, Xie G, Macciardi F, Selmi C, Lupoli S, Shigeta R, Ransom M, Lleo A, Lee AT, Mason AL, Myers RP, Peltekian KM, Ghent CN, Bernuzzi F, Zuin M, Rosina F, Borghesio E, Floreani A, Lazzari R Niro G, Andriulli A, Muratori L, Muratori P, Almasio PL, Andreone P, Margotti M, Brunetto M, Coco B, Alvaro D, Bragazzi MC, Marra F, Pisano A, Rigamonti C, Colombo M, Marzioni M, Benedetti A, Fabris L, Strazzabosco M, Portincasa P, Palmieri VO, Tiribelli C, Croce L, Bruno S, Rossi S, Vinci M, Prisco C, Mattalia A, Toniutto P, Picciotto A, Galli A, Ferrari C, Colombo S, Casella G, Morini L, Caporaso N, Colli A, Spinzi G, Montanari R, Gregersen PK, Heathcote EJ, Hirschfield GM, Siminovitch KA, Amos CI, Gershwin ME, Seldin MF (2010) Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet 42(8):658-660
79. Hirschfield GM, Liu X, Han Y, Gorlov IP, Lu Y, Xu C, Lu Y Chen W, Juran BD, Coltescu C, Mason AL, Milkiewicz P, Myers RP, Odin JA, Luketic VA, Speiciene D, Vincent C, Levy C, Gregersen PK, Zhang J, Heathcote EJ, Lazaridis KN, Amos CI, Siminovitch KA (2010) Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nat Genet 42(8):655-657
80. Juran BD, Atkinson EJ, Larson JJ, Schlicht EM, Liu X, Heathcote EJ, Hirschfield GM, Siminovitch KA, Lazaridis KN (2010) Carriage of a tumor necrosis factor polymorphism amplifies the cytotoxic T-lymphocyte antigen 4 attributed risk of primary biliary cirrhosis: evidence for a gene-gene interaction. Hepatology 52 (1):223-229
81. Selmi C, Mackay IR, Gershwin ME (2007) The immunological milieu of the liver. Semin Liver Dis 27(2):129-139 (Pubitemid 46871659)
82. Parikh-Patel A, Gold EB, Worman H, Krivy KE, Gershwin ME (2001) Risk factors for primary biliary cirrhosis in a cohort of patients from the united states. Hepatology 33(1):16-21 (Pubitemid 32016882)
83. Prince MI, Ducker SJ, James OF (2010) Case-control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations. Gut 59(4):508-512
84. Corpechot C, Chretien Y, Chazouilleres O, Poupon R (2010) Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. J Hepatol 53(1):162-169
85. Burroughs AK, Rosenstein IJ, Epstein O, Hamilton-Miller JM, Brumfitt W, Sherlock S (1984) Bacteriuria and primary biliary cirrhosis. Gut 25(2):133-137 (Pubitemid 14131405)
86. Butler P, Valle F, Hamilton-Miller JM, Brumfitt W, Baum H, Burroughs AK (1993) M2 mitochondrial antibodies and urinary rough mutant bacteria in patients with primary biliary cirrhosis and in patients with recurrent bacteriuria. J Hepatol 17(3):408-414 (Pubitemid 23134941)
87. Butler P, Hamilton-Miller JM, McIntyre N, Burroughs AK (1995) Natural history of bacteriuria in women with primary biliary cirrhosis and the effect of antimicrobial therapy in symptomatic and asymptomatic groups. Gut 36(6):931-934
88. Morreale M, Tsirigotis M, Hughes MD, Brumfitt W, McIntyre N Burroughs AK (1989) Significant bacteriuria has prognostic significance in primary biliary cirrhosis. J Hepatol 9(2):149-158 (Pubitemid 19224203)
89. Shimoda S, Nakamura M, Ishibashi H, Hayashida K, Niho Y (1995) HLA DRB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases. J Exp Med 181(5):1835-1845
90. Shimoda S, Nakamura M, Shigematsu H, Tanimoto H, Gushima T, Gershwin ME, Ishibashi H (2000) Mimicry peptides of human PDC-E2 163-176 peptide, the immunodominant T-cell epitope of primary biliary cirrhosis. Hepatology 31(6):1212-1216 (Pubitemid 30351280)
91. Shimoda S, Van de Water J, Ansari A, Nakamura M, Ishibashi H, Coppel RL, Lake J, Keeffe EB, Roche TE, Gershwin ME (1998) Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis. J Clin Invest 102(10):1831-1840 (Pubitemid 28533830)
92. Tanimoto H, Shimoda S, Nakamura M, Ishibashi H, Kawano A, Kamihira T, Matsushita S, Gershwin ME, Harada M (2003) Promiscuous T cells selected by Escherichia coli: OGDC-E2 in primary biliary cirrhosis. J Autoimmun 20(3):255-263 (Pubitemid 36561491)
93. Bogdanos DP, Baum H, Grasso A, Okamoto M, Butler P, Ma Y Rigopoulou E, Montalto P, Davies ET, Burroughs AK, Vergani D (2004) Microbial mimics are major targets ofcrossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. J Hepatol 40(1):31-39 (Pubitemid 38064710)
94. Bogdanos DP, Baum H, Sharma UC, Grasso A, Ma Y, Burroughs AK, Vergani D (2002) Antibodies against homolo-gous microbial caseinolytic proteases P characterise primary biliary cirrhosis. J Hepatol 36(1):14-21 (Pubitemid 34234011)
95. Bogdanos DP, Vergani D (2009) Bacteria and primary biliary cirrhosis. Clin Rev Allergy Immunol 36(1):30-39
96. Baum H, Bogdanos DP, Vergani D (2001) Antibodies to Clp protease in primary biliary cirrhosis: possible role of a mimicking T-cell epitope. J Hepatol 34(5):785-787 (Pubitemid 32488803)
97. Van de Water J, Ishibashi H, Coppel RL, Gershwin ME (2001) Molecular mimicry and primary biliary cirrhosis: premises not promises. Hepatology 33(4):771-775 (Pubitemid 32246623)
98. Palermo JJ (2008) Recurrent urinary tract infection in mice results in immune-mediated cholangiopathy similar to human primary biliary cirrhosis. Gastroenterology 134(4, suppl 1): A837
99. Burroughs AK, Butler P, Sternberg MJ, Baum H (1992) Molecular mimicry in liver disease. Nature 358(6385):377-378
100. Bogdanos DP, Baum H, Vergani D, Burroughs AK (2011) The role of E. coli infection in the pathogenesis of primary biliary cirrhosis. Disease Markers (in press)
101. Bogdanos DP, Baum H, Butler P, Rigopoulou EI, Davies ET, Ma Y, Burroughs AK, Vergani D (2003) Association between the primary biliary cirrhosis specific anti-sp100 antibodies and recurrent urinary tract infection. Dig Liver Dis 35(11):801-805 (Pubitemid 41070511)
102. Bogdanos DP, Baum H, Gunsar F, Arioli D, Polymeros D, Ma Y Burroughs AK, Vergani D (2004) Extensive homology between the major immunodominant mitochondrial antigen in primary biliary cirrhosis and Helicobacter pylori does not lead to immunological cross-reactivity. Scand J Gastroenterol 39 (10):981-987 (Pubitemid 39388463)
103. Bogdanos DP, Baum H, Okamoto M, Montalto P, Sharma UC, Rigopoulou EI, Vlachogiannakos J, Ma Y, Burroughs AK, Vergani D (2005) Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its Lactobacillus mimic. Hepatology 42(2):458-465 (Pubitemid 41061099)
104. Bogdanos DP, Choudhuri K, Vergani D (2001) Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver 21(4):225-232 (Pubitemid 32677377)
105. Selmi C, Meda F, Kasangian A, Invernizzi P, Tian Z, Lian Z, Podda M, Gershwin ME (2010) Experimental evidence on the immunopathogenesis of primary biliary cirrhosis. Cell Mol Immunol 7(1):1-10
106. Selmi C, Gershwin ME (2009) The role ofenvironmental factors in primary biliary cirrhosis. Trends Immunol 30(8):415-420
107. Koutsoumpas A, Mytilinaiou M, Polymeros D, Dalekos GN, Bogdanos DP (2009) Anti-Helicobacter pylori antibody responses specific for VacA do not trigger primary biliary cirrhosis-specific antimitochondrial antibodies. Eur J Gastro-enterol Hepatol 21(10):1220
108. Vergani D, Longhi MS, Bogdanos DP, Ma Y, Meli-Vergani G (2009) Autoimmune hepatitis. Semin Immunopathol 31(3):421-435
109. Wen L, Ma Y, Bogdanos DP, Wong FS, Demaine A, Mieli-Vergani G, Vergani D (2001) Pediatric autoimmune liver diseases: the molecular basis of humoral and cellular immunity. Curr Mol Med 1(3):379-389 (Pubitemid 33772964)
110. Selmi C, Balkwill DL, Invernizzi P, Ansari AA, Coppel RL, Podda M, Leung PS, Kenny TP, Van De Water J, Nantz MH, Kurth MJ, Gershwin ME (2003) Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic- metabolizing bacterium. Hepatology 38(5):1250-1257 (Pubitemid 37314834)
111. Polymeros D, Bogdanos DP, Day R, Arioli D, Vergani D, Forbes A (2006) Does cross-reactivity between mycobacterium avium paratuberculosis and human intestinal antigens characterize Crohn's disease? Gastroenterology 131(1):85-96 (Pubitemid 44015754)
112. Oldstone MB (1987) Molecular mimicry and autoimmune disease. Cell 50(6):819-820
113. Muratori L, Bogdanos DP, Muratori P, Lenzi M, Granito A, Ma Y Mieli-Vergani G, Bianchi FB, Vergani D (2005) Susceptibility to thyroid disorders in hepatitis C. Clin Gastroenterol Hepatol 3 (6):595-603 (Pubitemid 40824753)
114. Ma Y Bogdanos DP, Hussain MJ, Underhill J, Bansal S, Longhi MS, Cheeseman P, Mieli-Vergani G, Vergani D (2006) Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology 130(3):868-882 (Pubitemid 43374534)
115. Kerkar N, Choudhuri K, Ma Y, Mahmoud A, Bogdanos DP Muratori L, Bianchi F, Williams R, Mieli-Vergani G, Vergani D (2003) Cytochrome P4502D6(193-212): a new immunodomi-nant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J Immunol 170(3):1481-1489 (Pubitemid 36139518)
116. Gregorio GV, Choudhuri K, Ma Y, Pensati P, Iorio R, Grant P, Garson J, Bogdanos DP, Vegnente A, Mieli-Vergani G, Vergani D (2003) Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection. Clin Exp Immunol 133 (3):404-413 (Pubitemid 37046966)
117. Bogdanos DP, Mieli-Vergani G, Vergani D (2000) Virus, liver and autoimmunity Dig Liver Dis 32(5):440-446
118. Bogdanos DP, Muratori L, Bianchi FB, Vergani D (2000) Hepatitis C virus and autoimmunity. Hepatology 31(6):1380
119. Bogdanos DP, Pares A, Baum H, Caballeria L, Rigopoulou EI, Ma Y Burroughs AK, Rodes J, Vergani D (2004) Disease-specific cross-reactivity between mimicking peptides of heat shock protein of Mycobacterium gordonae and dominant epitope of E2 subunit of pyruvate dehydrogenase is common in Spanish but not British patients with primary biliary cirrhosis. J Auto-immun 22(4):353-362 (Pubitemid 38543228)
120. Bogdanos DP, Koutsoumpas A, Baum H, Vergani D (2006) Borrelia Burgdorferi: a new self-mimicking trigger in primary biliary cirrhosis. Dig Liver Dis 38(10):781-783
121. Bogdanos D, Pusl T, Rust C, Vergani D, Beuers U (2008) Primary biliary cirrhosis following lactobacillus vaccination for recurrent vaginitis. J Hepatol 49(3):466-473
122. Baum H (1995) Mitochondrial antigens, molecular mimicry and autoimmune disease. Biochim Biophys Acta 1271(1):111-121
123. Alvaro D, Invernizzi P, Onori P, Franchitto A, De Santis A, Crosignani A, Sferra R, Ginanni-Corradini S, Mancino MG, Maggioni M, Attili AF, Podda M, Gaudio E (2004) Estrogen receptors in cholangiocytes and the progression of primary biliary cirrhosis. J Hepatol 41(6):905-912 (Pubitemid 39575656)
124. Amano K, Leung PS, Rieger R, Quan C, Wang X, Marik J, Suen YF, Kurth MJ, Nantz MH, Ansari AA, Lam KS, Zeniya M, Matsuura E, Coppel RL, Gershwin ME (2005) Chemical xeno-biotics and mitochondrial autoantigens in primary biliary cirrhosis: identification of antibodies against a common environmental, cosmetic, and food additive, 2-octynoic acid. J Immunol 174 (9):5874-5883 (Pubitemid 40593233)
125. Amano K, Leung PS, Xu Q, Marik J, Quan C, Kurth MJ, Nantz MH, Ansari AA, Lam KS, Zeniya M, Coppel RL, Gershwin ME (2004) Xenobiotic-induced loss of tolerance in rabbits to the mitochondrial autoantigen of primary biliary cirrhosis is reversible. J Immunol 172(10):6444-6452 (Pubitemid 38621254)
126. Long SA, Quan C, Van de Water J, Nantz MH, Kurth MJ, Barsky D, Colvin ME, Lam KS, Coppel RL, Ansari A, Gershwin ME (2001) Immunoreactivity oforganic mimeotopes of the E2 component of pyruvate dehydrogenase: connecting xeno-biotics with primary biliary cirrhosis. J Immunol 167(5):2956-2963 (Pubitemid 32768932)
127. Selmi C, Ichiki Y, Invernizzi P, Podda M, Gershwin ME (2005) The enigma of primary biliary cirrhosis. Clin Rev Allergy Immunol 28(2):73-81 (Pubitemid 41264854)
128. Triger DR (1980) Primary biliary cirrhosis: an epidemiological study. Br Med J 281(6243):772-775 (Pubitemid 10048546)
129. Smyk D, Mytilinaiou MG, Rigopoulou EI, Bogdanos DP (2011) PBC triggers in water reservoirs, coal mining areas and waste disposal sites: from Newcastle to New York. Dis Markers 29:337-344
130. Ala A, Stanca CM, Bu-Ghanim M, Ahmado I, Branch AD, Schiano TD, Odin JA, Bach N (2006) Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites. Hepatology 43(3):525-531
131. Stellon AJ, Williams R (1986) Increased incidence ofmenstrual abnormalities and hysterectomy preceding primary biliary cirrhosis. Br Med J Clin Res Ed 293(6542):297-298 (Pubitemid 16070826)
132. Alvaro D, Mancino MG, Onori P, Franchitto A, Alpini G, Francis H, Glaser S, Gaudio E (2006) Estrogens and the pathophysiology of the biliary tree. World J Gastroenterol 12 (22):3537-3545 (Pubitemid 43997030)
133. Alvaro D, Onori P, Metalli VD, Svegliati-Baroni G, Folli F, Franchitto A, Alpini G, Mancino MG, Attili AF, Gaudio E (2002) Intracellular pathways mediating estrogen-induced cholangiocyte proliferation in the rat Hepatology 36(2):297-304 (Pubitemid 34810348)
134. Fagan E, Williams R, Cox S (1977) Primary biliary cirrhosis in mother and daughter. Br Med J 2(6096):1195 (Pubitemid 8215621)
135. Brind AM, Bray GP, Portmann BC, Williams R (1995) Prevalence and pattern of familial disease in primary biliary cirrhosis. Gut 36(4):615-617
136. Lazaridis KN, Juran BD, Boe GM, Slusser JP, de Andrade M, Homburger HA, Ghosh K, Dickson ER, Lindor KD, Petersen GM (2007) Increased prevalence of antimitochondrial anti-bodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology 46(3):785-792 (Pubitemid 47436125)
137. Bach N, Schaffner F (1994) Familial primary biliary cirrhosis. J Hepatol 20(6):698-701 (Pubitemid 24216878)
138. Floreani A, Naccarato R, Chiaramonte M (1997) Prevalence of familial disease in primary biliary cirrhosis in Italy. J Hepatol 26 (3):737-738 (Pubitemid 27112743)
139. Tsuji K, Watanabe Y, Van De Water J, Nakanishi T, Kajiyama G, Parikh-Patel A, Coppel R, Gershwin ME (1999) Familial primary biliary cirrhosis in Hiroshima. JAutoimmun 13(1):171-178 (Pubitemid 29367022)
140. Selmi C, Invernizzi P, Zuin M, Podda M, Gershwin ME (2005) Genetics and geoepidemiology of primary biliary cirrhosis: following the footprints to disease etiology Semin Liver Dis 25(3):265-280 (Pubitemid 41254575)
141. Selmi C, Invernizzi P, Zuin M, Podda M, Seldin MF, Gershwin ME (2005) Genes and (auto)immunity in primary biliary cirrhosis. Genes Immun 6(7):543-556 (Pubitemid 41637662)
142. Hemminki K, Li X, Sundquist K, Sundquist J (2009) Shared familial aggregation of susceptibility to autoimmune diseases. Arthritis Rheum 60(9):2845-2847
143. Metcalf JV, Mitchison HC, Palmer JM, Jones DE, Bassendine MF, James OF (1996) Natural history of early primary biliary cirrhosis. Lancet 348(9039):1399-1402 (Pubitemid 26395233)
144. Leung PS, Coppel RL, Ansari A, Munoz S, Gershwin ME (1997) Antimitochondrial antibodies in primary biliary cirrhosis. Semin Liver Dis 17(1):61-69 (Pubitemid 27157372)
145. Bogdanos DP, Vergani D (2006) Origin of cross-reactive autoim-munity in primary biliary cirrhosis. Liver Int 26(6):633-635 (Pubitemid 43983878)
146. EASL (2009) Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 51(2):237-267
147. Gershwin ME, Goetzl EJ, Steinberg AD (1974) Cyclophospha-mide: use in practice. Ann Intern Med 80(4):531-540
148. Hershko AY, Naparstek Y (2006) Autoimmunity in the era of genomics and proteomics. Autoimmun Rev 5(4):230-233 (Pubitemid 43668458)
149. Bizzaro N, Tozzoli R, Shoenfeld Y (2007) Are we at a stage to predict autoimmune rheumatic diseases? Arthritis Rheum 56 (6):1736-1744 (Pubitemid 47110373)
150. Tonutti E, Visentini D, Bizzaro N (2007) Interpretative com-ments on autoantibody tests. Autoimmun Rev 6(6):341-346
151. Martin PI, Malizia AI, Rewald E (2008) A propos time and autoimmunity. Clin Rev Allergy Immunol 34(3):380-384
152. Shoenfeld Y Selmi C, Zimlichman E, Gershwin ME (2008) The autoimmunologist: geoepidemiology, a new center of gravity, and prime time for autoimmunity. J Autoimmun 31(4):325-330
153. Berkun Y Padeh S (2010) Environmental factors and the geoepidemiology of juvenile idiopathic arthritis. Autoimmun Rev 9(5):A319-A324
154. Bhat A, Naguwa S, Cheema G, Gershwin ME (2010) The epidemiology of transverse myelitis. Autoimmun Rev 9(5): A395-A399
155. Biggioggero M, Meroni PL (2010) The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev 9(5): A299-A304
156. Borchers AT, Naguwa SM, Keen CL, Gershwin ME (2010) The implications of autoimmunity and pregnancy. J Autoimmun 34 (3):J287-J299
157. Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME (2010) The geoepidemiology of systemic lupus erythematosus. Auto-immun Rev 9(5):A277-A287
158. Borchers AT, Uibo R, Gershwin ME (2010) The geoepidemiology oftype 1 diabetes. Autoimmun Rev 9(5):A355-A365
159. Brooks WH, Le Dantec C,PersJO, Youinou P, Renaudineau Y (2010) Epigenetics and autoimmunity. JAutoimmun 34(3):J207-J219
160. Chandran V, Raychaudhuri SP (2010) Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 34(3):J314-J321
161. Chang C (2010) The immune effects ofnaturally occurring and synthetic nanoparticles. J Autoimmun 34(3):J234-J246
162. Chen M, Daha MR Kallenberg CG (2010) The complement system in systemic autoimmune disease. J Autoimmun 34(3):J276-J286
163. Chen M, Kallenberg CG (2010) The environment, geoepidemiology and ANCA-associated vasculitides. Autoimmun Rev 9(5):A293-A298
164. Deane S, Teuber SS, Gershwin ME (2010) The geoepidemiology of immune thrombocytopenic purpura. Autoimmun Rev 9(5): A342-A349
165. Ehrenfeld M (2010) Geoepidemiology: the environment and spondyloarthropathies. Autoimmun Rev 9(5)A325-A329
166. Hemminki K, Li X, Sundquist J, Sundquist K (2010) The epidemiology of Graves' disease: evidence of a genetic and an environmental contribution. J Autoimmun 34(3):J307-J313
167. Hoffmann MH, Trembleau S, Muller S, Steiner G (2010) Nucleic acid-associated autoantigens: pathogenic involvement and therapeutic potential. J Autoimmun 34(3):J178-J206
168. Invernizzi P (2010) Geoepidemiology of autoimmune liver diseases. J Autoimmun 34(3):J300-J306
169. Lambert JF, Nydegger UE (2010) Geoepidemiology of autoim-mune hemolytic anemia. Autoimmun Rev 9(5)A350-A354
170. Leung PS, Shu SA, Kenny TP, Wu PY, Tao MH (2010) Development and validation of gene therapies in autoimmune diseases: epidemi-ology to animal models. Autoimmun Rev 9(5)A400-A405
171. Lleo A, Invernizzi P, Gao B, Podda M, Gershwin ME (2010) Definition of human autoimmunity-autoantibodies versus auto-immune disease. Autoimmun Rev 9(5)A259-A266
172. Logan I, Bowlus CL (2010) The geoepidemiology of autoim-mune intestinal diseases. Autoimmun Rev 9(5):A372-A378
173. Mackay IR (2010) Travels and travails of autoimmunity: a historical journey from discovery to rediscovery. Autoimmun Rev 9(5):A251-A258
174. Mavragani CP, Moutsopoulos HM (2010) The geoepidemiology ofSjogren's syndrome. Autoimmun Rev 9(5)A305-A310
175. Meyer A, Levy Y (2010) Chapter 33: geoepidemiology of myasthenia gravis. Autoimmun Rev 9(5)A383-A386
176. Meyer N, Misery L (2010) Geoepidemiologic considerations of auto-immune pemphigus. Autoimmun Rev 9(5):A379-A382
177. Milo R, Kahana E (2010) Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 9(5):A387-A394
178. Powell JJ, Faria N, Thomas-McKay E, Pele LC (2010) Origin and fate of dietary nanoparticles and microparticles in the gastrointestinal tract. J Autoimmun 34(3):J226-J233
179. Prieto S, Grau JM (2010) The geoepidemiology of autoimmune muscle disease. Autoimmun Rev 9(5)A330-A334
180. Ranque B, Mouthon L (2010) Geoepidemiology of systemic sclerosis. Autoimmun Rev 9(5):A311-A318
181. Round JL, O'Connell RM, Mazmanian SK (2010) Coordination of tolerogenic immune responses by the commensal microbiota. J Autoimmun 34(3):J220-J225
182. Sands J, Tuscano JM (2010) Geoepidemiology and autoimmune manifestations of lymphoproliferative disorders. Autoimmun Rev 9(5)A335-A341
183. Segelmark M, Hellmark T (2010) Autoimmune kidney diseases. Autoimmun Rev 9(5)A366-A371
184. Selmi C (2010) The worldwide gradient of autoimmune conditions. Autoimmun Rev 9(5):A247-A250
185. Selmi C, Tsuneyama K (2010) Nutrition, geoepidemiology, and autoimmunity. Autoimmun Rev 9(5):A267-A270
186. Shapira Y, Agmon-Levin N, Shoenfeld Y (2010) Defining and analyzing geoepidemiology and human autoimmunity. J Auto-immun 34(3):J168-J177
187. Stojanovich L (2010) Stress and autoimmunity. Autoimmun Rev 9(5)A271-A276
188. Tobon GJ, Youinou P, Saraux A (2010) The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. Autoimmun Rev 9(5)A288-A292
189. Tomer Y (2010) Hepatitis C and interferon induced thyroiditis. J Autoimmun 34(3):J322-J326
190. Zeki AA, Schivo M, Chan AL, Hardin KA, Kenyon NJ, Albertson TE et al (2010) Geoepidemiology of COPD and idiopathic pulmonary fibrosis. J Autoimmun 34(3):J327-J338